Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Metformin
50%
Hemoglobin A1c (HbA1c)
40%
Diabetes
38%
Sulfonylurea
34%
Glycemic Response
20%
Precision Medicine
19%
Dipeptidyl peptidase-4 (DPP-4)
18%
Type 1 Diabetes Mellitus (T1DM)
17%
Type 2 Diabetic Patients
15%
Insulin Resistance
13%
Thiazolidinediones
13%
Monogenic Diabetes
13%
Insulin
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Organic Cation Transporter 1
12%
Glycaemic Deterioration
12%
Type I Diabetes
11%
Genotype
11%
Glucose-lowering Drugs
10%
Diabetes Management
9%
β-cell Function
9%
C-peptide
9%
Meta-analysis
9%
Third-line Therapy
9%
Drug Response
8%
Hypoglycemia
8%
Gastrointestinal Tolerance
8%
Innovative Medicines Initiative
8%
Pharmacogenomics
7%
Glucagon-like
7%
Obesity
7%
Pharmacogenetics
7%
Patient Stratification
6%
Second-line Therapy
6%
Clinical Characteristics
6%
Genetic Variants
6%
Metformin Response
6%
Pharmacokinetics
6%
Type 2 Diabetes Risk
6%
Insulin Therapy
6%
Gliclazide
6%
Inhibitor Therapy
6%
Confidence Interval
6%
American Diabetes Association
5%
Disease Progression
5%
Metformin Intolerance
5%
Clinical Practice Research Datalink
5%
Metformin Treatment
5%
European Associations
5%
Metabolic Biomarkers
5%
Consensus Document
5%
Systematic Meta-analysis
5%
Risk Factors
5%
Population-based
5%
CYP2C9
5%
Cardiometabolic Disease
5%
Intolerance
5%
Scotland
5%
UK Biobank
5%
Hazard Ratio
5%
Diabetes Drugs
5%
Clinical Features
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
75%
Diabetes
60%
Glycon
36%
Hemoglobin A1c
28%
Sulfonylurea
25%
Glycemic
24%
Personalized Medicine
18%
Body Mass Index
14%
Biological Marker
12%
Cohort Analysis
11%
Patient with Type 2 Diabetes
11%
Organic Cation Transporter 1
10%
Dipeptidyl Peptidase-4 Inhibitor
10%
Side Effect
9%
Beta Cell
8%
Cell Function
8%
Thiazolidinedione
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Drug Response
8%
Insulin Resistance
7%
Allele
6%
Diabetes Mellitus
6%
Medicine
6%
Hypoglycemia
6%
Drug Therapy
6%
Insulin Treatment
6%
Insulin Dependent Diabetes Mellitus
6%
Deterioration
6%
Low Drug Dose
6%
Primary Health Care
5%
Glucagon Like Peptide 1
5%
Incretin
5%
Asian Indians
5%
Meta-Analysis
5%
Hazard Ratio
5%
Biochemistry, Genetics and Molecular Biology
Genetics
34%
Sulfonylurea
19%
C-Peptide
18%
Allele
14%
Insulin Resistance
14%
Genotyping
14%
Glucose Blood Level
10%
Genetic Divergence
9%
Body Mass
9%
Cell Function
9%
Polygenic Score
8%
Pharmacogenetics
8%
Randomized Controlled Trial
8%
Tamsulosin
7%
Pharmacogenomics
7%
Blood Plasma
7%
Autoantibodies
6%
Dipeptidyl Peptidase-4
6%
Prevalence
6%
HDL-Cholesterol
6%
Transporter Genes
5%
Metabolomics
5%
Genetic Risk
5%
Pharmacokinetics
5%
Genome Wide Association Study
5%
Glucagon-Like Peptide 1 Receptor
5%
Receptor Agonists
5%
HNF1A
5%
Creatinine
5%
Cohort Study
5%
Metabolite
5%
Transfer RNA
5%
Low Drug Dose
5%
Thiazolidinedione
5%